实用肿瘤学杂志 ›› 2025, Vol. 39 ›› Issue (6): 515-526.doi: 10.11904/j.issn.1002-3070.2025.06.009

• 基础研究 • 上一篇    下一篇

基于网络药理学和分子对接探讨洛莫司汀治疗脑胶质瘤的作用机理

任梦1, 李岚君2, 高燕3   

  1. 1.内蒙古医科大学附属医院急诊科(呼和浩特 010050);
    2.内蒙古医科大学附属医院康复科;
    3.首都医科大学附属北京妇产医院中心实验室
  • 收稿日期:2025-10-20 修回日期:2025-12-04 出版日期:2025-12-28 发布日期:2026-01-13
  • 通讯作者: 高燕,E-mail:gy19861@ccmu.edu.cn
  • 作者简介:任梦,女,(1993—),硕士,主治医师,从事心脑血管疾病方面的研究。
  • 基金资助:
    首都医科大学附属北京妇产医院/北京妇幼保健院科技创新及转化专项(编号:FCYYJC202401)

Exploring the mechanism of lomustine treatment of glioma based on network pharmacology and molecular docking

REN Meng1, LI Lanjun2, GAO Yan3   

  1. 1. Department of Emergency,affiliated Hospital of Inner Mongolia Medical University,Hohhot 010050,China;
    2. Department of Physical Medicine and Rehabilitation,Affiliated Hospital of Inner Mongolia Medical University;
    3 Central Laboratory,Beijing Obstetrics and Gynecology Hospital,Capital Medical University,Beijing Maternal and Child Health Care Hospital
  • Received:2025-10-20 Revised:2025-12-04 Online:2025-12-28 Published:2026-01-13

摘要: 目的 基于网络药理学、分子对接与分子动力学模拟等方法,探讨洛莫司汀治疗脑胶质瘤的潜在作用靶点及其分子机制,为临床精准用药提供理论依据。方法 检索SwissTargetPrediction、Comparative Toxicogenomics Database、GeneCards数据库获得药物候选靶点,通过STRING数据库构建蛋白质-蛋白质相互作用(protein-protein interaction,PPI)网络筛选核心靶点,对核心靶点进行GO功能富集分析。采用分子对接技术预测洛莫司汀与核心靶点的结合模式与结合能,并通过分子动力学模拟及相关方法评估靶点结合稳定性。利用GEPIA数据库进行差异表达及生存分析,评估最终分析靶点基因与患者总生存期(overall survival,OS)和无病生存期(disease-free survival,DFS)的相关性。最后,通过体外实验评估最终确定靶点CDKN1A敲低与洛莫司汀处理对人胶质瘤细胞系U-87MG生物学行为的影响。采用RT-qPCR和免疫印迹法检测U-87MG细胞中CDKN1A敲低后mRNA表达和蛋白的表达水平;划痕实验检测细胞迁移能力;CCK-8法检测细胞增殖能力;流式细胞术检测细胞凋亡情况。结果 筛选获得洛莫司汀潜在靶点113个、脑胶质瘤相关靶点3 935个,取交集获得10个候选靶点。经PPI网络筛选出6个核心靶点,随后分子对接进一步筛选出5个最终分析靶点,分子动力学模拟结果最终确定CDKN1A为核心作用靶点。该靶点主要定位于细胞核在脑胶质瘤组织中高表达且与OS和DFS相关(P<0.05)。体外实验显示,在U-87MG胶质瘤细胞中CDKN1A基因敲低与洛莫司汀处理均能显著抑制细胞迁移与增殖(P<0.01),并促进细胞凋亡(P<0.05),且二者作用效果相当。结论 CDKN1A可能是洛莫司汀治疗脑胶质瘤的关键潜在靶点,为深入阐明洛莫司汀的抗胶质瘤作用机制及其临床应用提供了新的理论依据。

关键词: 脑胶质瘤, 洛莫司汀, 分子动力学模拟, 分子对接

Abstract: Objective Based on methods such as network pharmacology,molecular docking and molecular dynamic simulation,this study aimed to explore the potential targets and molecular mechanism of lomustine in the treatment of glioma,providing a theoretical basis for clinical precision medicine. Methods Potential drug targets were obtained by searching SwissTargetPrediction,Comparative Toxicogenomics database,and Genecards databases.Protein-protein interaction(PPI)networks were constructed through the STRING database to screen core targets,and perform GO functional enrichment analysis on the core targets.Molecular docking technology was used to predict the binding mode and binding energy between lomustine and core targets,and evaluate the stability of target binding through molecular dynamics simulation and related methods.Differential expression and survival analysis were performed using the GEPIA database,and the correlation between the final core target genes and overall survival(OS)and disease-free survival(DFS)of patients was assessed.Finally,in vitro experiments were performed to evaluate the effects of targetCDKN1A knockdown and lomustine treatment on the biological behaviors of the human glioma U-87MG cells.RT-qPCR and Western blot were used to detect the levels of CDKN1A knockdown at mRNA and protein expression in U-87MG cells.Wound healing assay was conducted to evaluate cell migration ability;CCK-8 assay was used to assess cell proliferation ability;Flow cytometry was performed to detect cell apoptosis in U-87MG cells. Results As a result of screening,113 potential targets of lomustine and 3 935 targets associated with glioma were identified,and 10 candidate targets were obtained by taking the intersection.Six core targets were identified through PPI network screening,followed by further screening of five final analytical targets through molecular docking.Molecular dynamic simulation ultimately determined CDKN1A as the core target of action.This target was highly expressed in glioma tissues and was associated with poor OS and DFS(P<0.05),mainly localized in the nucleus.knockdown of CDKN1A gene and lomustine treatment could significantly inhibit cell migration and proliferation(P<0.01),and promoted apoptosis(P<0.05)in U-87MG cells,and their effects were comparable. Conclusion CDKN1A may be as a key potential target for the treatment of glioblastoma with lomustine,providing new theoretical basis for further elucidating the anti-glioma mechanism and clinical application of lomustine.

Key words: glioma, lomustine, molecular dynamics simulation, molecular docking

中图分类号: